Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.39 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 3/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7886926 | 0.77 | C5AR1 (0.45) | OPRM1OPRK1OPRL1C5AR1BRD4 | |
| SCHEMBL13041624 | 0.69 | C5AR1 (0.47) | OPRM1OPRK1OPRL1C5AR1PARP1 | |
| SCHEMBL13041627 | 0.68 | ALDH1A1 (0.42) | OPRM1OPRK1OPRL1SMN1; SMN2CYP2D6 | |
| SCHEMBL2873256 | 0.66 | BRD4 (0.38) | BRD4PARP1ALDH1A1 | |
| SCHEMBL25061783 | 0.65 | OPRM1 (0.31) | OPRM1OPRL1 | |
| SCHEMBL28227456 | 0.65 | ALDH1A1 (0.41) | OPRM1OPRK1OPRL1SMN1; SMN2CYP2D6 | |
| SCHEMBL38660167 | 0.65 | ALDH1A1 (0.41) | OPRM1OPRK1OPRL1SMN1; SMN2CYP2D6 | |
| SCHEMBL13041636 | 0.64 | C5AR1 (0.45) | OPRM1OPRK1OPRL1C5AR1PARP1 | |
| SCHEMBL14169822 | 0.63 | SLC6A2 (0.38) | OPRM1OPRK1OPRL1SMN1; SMN2CYP2D6 | |
| SCHEMBL13041646 | 0.62 | MAPK1 (0.47) | C5AR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | OPRM1 1102/4885OPRK1 1881/4885OPRL1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.